GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunmax Biotechnology Co 4728.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

392.00

—

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 2.03bn

FY2016FY2025

Net income

TWD 725.7m

FY2016FY2025

Free cash flow

TWD 757.6m

FY2016FY2025

Shareholders' equity

TWD 1.62bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 2.03bnTWD 1.82bnTWD 1.69bnTWD 1.40bnTWD 1.04bnTWD 855.9mTWD 594.1mTWD 304.1mTWD 190.1mTWD 155.5m
Gross profitTWD 1.59bnTWD 1.48bnTWD 1.40bnTWD 1.19bnTWD 894.4mTWD 701.2mTWD 514.2mTWD 240.3mTWD 137.6mTWD 99.1m
Research and developmentTWD 42.2mTWD 39.2mTWD 28.7mTWD 18.0mTWD 24.6mTWD 17.5mTWD 22.6mTWD 19.5mTWD 11.8mTWD 19.5m
Operating incomeTWD 998.3mTWD 927.0mTWD 912.5mTWD 777.7mTWD 362.6mTWD 346.4mTWD 177.5mTWD 63.9mTWD 13.3mTWD 3.1m
Net incomeTWD 725.7mTWD 679.4mTWD 625.7mTWD 533.8mTWD 245.6mTWD 238.1mTWD 100.4mTWD 74.7mTWD 16.5mTWD 1.7m
Diluted earnings per share13.3312.4811.479.804.514.371.841.370.310.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 2.12bnTWD 2.09bnTWD 2.16bnTWD 1.79bnTWD 1.48bnTWD 1.36bnTWD 1.11bnTWD 757.9mTWD 660.9mTWD 597.5m
Cash and short-term investments——TWD 961.8mTWD 816.7mTWD 679.3mTWD 909.6m————
Total liabilitiesTWD 505.6mTWD 582.1mTWD 733.0mTWD 468.0mTWD 460.4mTWD 475.3mTWD 435.8mTWD 109.9mTWD 88.2mTWD 42.2m
Debt—TWD 145.2mTWD 169.0mTWD 63.1mTWD 99.2mTWD 130.0mTWD 117.0mTWD 24.0mTWD 24.0m—
Shareholders' equityTWD 1.62bnTWD 1.51bnTWD 1.43bnTWD 1.33bnTWD 1.02bnTWD 888.8mTWD 676.8mTWD 648.0mTWD 572.7mTWD 555.3m
Shares outstanding54m54m55m54m54m54m54m54m54m54m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 825.9mTWD 561.0mTWD 848.6mTWD 343.0mTWD 243.3mTWD 387.0mTWD 289.5mTWD 100.8mTWD 37.1mTWD 16.6m
Capital spending−TWD 68.3m−TWD 37.0m−TWD 110.4m−TWD 152.0m−TWD 255.4m−TWD 130.1m−TWD 13.7m−TWD 4.7m−TWD 3.2m−TWD 4.7m
Free cash flowTWD 757.6mTWD 524.0mTWD 738.2mTWD 190.9m−TWD 12.1mTWD 256.9mTWD 275.8mTWD 96.1mTWD 33.9mTWD 11.9m
Dividends paid−TWD 631.8m−TWD 599.1m−TWD 517.4m−TWD 239.6m−TWD 108.9m−TWD 81.7m−TWD 65.4m−TWD 16.2m−TWD 16.2m−TWD 16.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 618.3mTWD 564.8mTWD 508.3mTWD 503.6mTWD 460.1mTWD 554.2m−TWD 389.7mTWD 457.5m
Gross profitTWD 506.2mTWD 445.7mTWD 391.5mTWD 392.2mTWD 364.0mTWD 440.9m−TWD 361.3mTWD 363.4m
Operating incomeTWD 329.3mTWD 292.4mTWD 213.3mTWD 258.6mTWD 220.8mTWD 305.6mTWD 88.0mTWD 233.1m
Net incomeTWD 242.4mTWD 221.6mTWD 157.8mTWD 189.7mTWD 154.9mTWD 223.3mTWD 149.0mTWD 171.6m
Diluted earnings per share4.454.072.903.482.844.102.743.15
Cash from operationsTWD 269.0mTWD 269.0mTWD 259.0mTWD 160.0mTWD 131.0mTWD 273.0mTWD 75.0mTWD 98.0m
Capital spending−TWD 5.0m−TWD 31.0m−TWD 43.0m−TWD 17.0m−TWD 2.0m−TWD 4.0m−TWD 9.0m−TWD 5.0m
Free cash flowTWD 264.0mTWD 238.0mTWD 216.0mTWD 143.0mTWD 129.0mTWD 269.0mTWD 66.0mTWD 93.0m
Total assetsTWD 2.00bnTWD 2.38bnTWD 2.12bnTWD 1.90bnTWD 2.39bnTWD 2.31bnTWD 2.09bnTWD 1.87bn
Shareholders' equityTWD 1.43bnTWD 1.19bnTWD 1.62bnTWD 1.44bnTWD 1.24bnTWD 1.11bnTWD 1.51bnTWD 1.37bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin78.4%81.3%83.2%85.2%86.4%81.9%——
Operating margin49.3%51.0%54.0%55.5%35.0%40.5%——
Net margin35.8%37.4%37.0%38.1%23.7%27.8%——
Return on equity44.9%44.9%43.9%40.3%24.0%26.8%——
Return on assets34.2%32.4%29.0%29.8%16.6%17.5%——
Free cash flow yield—2.8%4.5%2.3%2.3%2.4%1.4%—
Revenue growth11.4%7.6%20.6%35.2%21.0%44.0%——
Earnings growth6.8%8.6%17.2%117.3%3.2%137.0%——
Current ratio3.89x3.32x2.36x2.78x2.36x3.28x——
Debt to equity——0.02x0.02x0.04x0.03x0.01x0.04x
Equity ratio76.2%72.2%66.1%73.9%69.0%65.2%——
Interest coverage204.40x155.74x310.15x578.20x129.24x118.85x——
R&D as a share of sales2.1%2.2%1.7%1.3%2.4%2.0%——
Buybacks as a share of market value—0.2%-0.1%0.0%0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue13.1%18.8%33.6%
Operating income8.7%23.6%—
Net income10.8%25.0%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin79.8%81.7%82.3%81.7%
Operating margin50.1%52.1%49.0%44.5%
Net margin36.6%37.0%34.5%31.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings29.722.417.813.918.318.443.534.690.6—
Price to sales10.68.46.65.34.35.17.38.57.914.8

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 31 Mar 2026.

FY2026FY2025FY2024FY2023FY2022
Paid in the year12.1011.6011.009.504.40

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.